{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:30:21Z","timestamp":1791599421511,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejmech.2021.113222","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T21:58:01Z","timestamp":1611611881000},"page":"113222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M\/HER2 inhibitors: Design, synthesis, structure\u2013activity relationship and biological activity as potential antitumor and anticonvulsant agents"],"prefix":"10.1016","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2477-4900","authenticated-orcid":false,"given":"Phoebe F.","family":"Lamie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa M.","family":"El-Kalaawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha S.","family":"Abdel Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila A.","family":"Rashed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N.","family":"Philoppes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113222_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signalling","volume":"411","author":"Jensen","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113222_bib2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1021\/ml300327z","article-title":"Structure-based approach for the discovery of pyrrolo[3,2-d]pyrimidine-based EGFR T790M\/L858R mutant Inhibitors","volume":"4","author":"Sogabe","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113222_bib3","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/cbdd.12451","article-title":"4-Substituted-1-phenyl-1\u03bc\u03bcH-pyrazolo[3,4-d]pyrimidine derivatives: design, synthesis, antitumor and EGFR tyrosine kKinase inhibitory activity","volume":"85","author":"Abbas","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2021.113222_bib4","doi-asserted-by":"crossref","first-page":"15411","DOI":"10.1007\/s13277-016-5467-2","article-title":"Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms","volume":"37","author":"Shi","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ejmech.2021.113222_bib5","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR Antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2021.113222_bib6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2021.113222_bib7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF-ERBB signalling: towards the systems level","volume":"7","author":"Citri","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2021.113222_bib8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ejmech.2018.06.011","article-title":"Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR\/HER2 inhibitors","volume":"155","author":"Milik","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113222_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev.med.55.091902.104433","article-title":"The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors","volume":"55","author":"Rowinsky","year":"2004","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejmech.2021.113222_bib10","series-title":"The 10 Most Common Causes of Cancer Death, World, 2012 Estimates","author":"Cancer Research UK","year":"2014"},{"key":"10.1016\/j.ejmech.2021.113222_bib11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/med.20070","article-title":"Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development","volume":"26","author":"Kamath","year":"2006","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2021.113222_bib12","first-page":"67","article-title":"Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations \u2014 a review, Transl","volume":"4","author":"Stewart","year":"2015","journal-title":"Lung Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113222_bib13","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","article-title":"HER2 Amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation","volume":"2","author":"Takezawa","year":"2012","journal-title":"Canc. Discov."},{"key":"10.1016\/j.ejmech.2021.113222_bib14","doi-asserted-by":"crossref","first-page":"7725","DOI":"10.1021\/acs.jmedchem.7b00515","article-title":"Structure-guided development of covalent and mutant-selective pyrazolopyrimidines to target T790M Drug Resistance in epidermal growth factor receptor","volume":"60","author":"Engel","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113222_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejps.2014.04.011","article-title":"Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d] pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity","volume":"59","author":"Kaspersen","year":"2014","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2021.113222_bib16","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2021.113222_bib17","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2021.113222_bib18","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1021\/jm201507x","article-title":"Irreversible inhibition of epidermal growth factor receptor activity by 3 aminopropanamides","volume":"55","author":"Carmi","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113222_bib19","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-13-0314","article-title":"Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC","volume":"3","author":"Walter","year":"2013","journal-title":"Canc. Discov."},{"key":"10.1016\/j.ejmech.2021.113222_bib20","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an Irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Canc. Discov."},{"key":"10.1016\/j.ejmech.2021.113222_bib21","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/annonc\/mdw140","article-title":"Rociletinib: has the TIGER lost a few of its stripes?","volume":"27","author":"Dhingra","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2021.113222_bib22","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.2147\/OTT.S97644","article-title":"New developments in the management of nonsmall- cell lung cancer, focus on rociletinib: what went wrong?","volume":"9","author":"Van Der Steen","year":"2016","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2021.113222_bib23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","article-title":"Osimertinib: first global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2021.113222_bib24","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"Janne","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2021.113222_bib25","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s00044-014-1315-3","article-title":"Anticonvulsant activity of 1,2,4-triazine derivatives with pyridyl side chain: synthesis, biological, and computational study","volume":"24","author":"Irannejad","year":"2015","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2021.113222_bib26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1631\/jzus.2007.B0526","article-title":"Synthesis and anticonvulsant activity of some potent 5,6-bis aryl 1,2,4-triazines","volume":"8","author":"Mallikarjuna","year":"2007","journal-title":"Zhejiang Univ. Sci. B"},{"key":"10.1016\/j.ejmech.2021.113222_bib27","series-title":"Pediatric Epilepsy: Diagnosis and Therapy","first-page":"117","author":"Prasad","year":"2001"},{"key":"10.1016\/j.ejmech.2021.113222_bib28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pneurobio.2007.10.010","article-title":"Progress in neuroprotective strategies for preventing epilepsy","volume":"84","author":"Acharya","year":"2008","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejmech.2021.113222_bib29","series-title":"The Treatment of Epilepsy","first-page":"123","year":"2009"},{"key":"10.1016\/j.ejmech.2021.113222_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2004.07.010","article-title":"Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)","volume":"61","author":"Bialer","year":"2004","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejmech.2021.113222_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ardp.201400045","article-title":"Design, synthesis, and biological evaluation of hydrazine incorporated 1,2,4-triazines as anticonvulsant agents","volume":"347","author":"Amir","year":"2014","journal-title":"Arch. Pharm. Chem. Life Sci."},{"key":"10.1016\/j.ejmech.2021.113222_bib32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.bmcl.2011.11.007","article-title":"Synthesis and anticonvulsant evaluation of some new 2,3,8-trisubstituted-4(3H)-quinazoline derivatives","volume":"22","author":"El-Azab","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113222_bib33","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1016\/j.ejmech.2010.05.049","article-title":"N\u2019-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene] 2\/4-substituted hydrazides: synthesis and anticonvulsant activity","volume":"45","author":"Kaushik","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113222_bib34","first-page":"29","article-title":"Comparative anticonvulsant potency and pharmacokinetics of (+)- and (\u2212)-enantiomers of stiripentol","volume":"1","author":"Danny","year":"1992","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejmech.2021.113222_bib35","first-page":"4097","article-title":"Synthesis and antitumor activity of novel pyrazolo[3,4-d]pyrimidin-4(5H)-one derivatives","volume":"4","author":"Kandeel","year":"2012","journal-title":"J.\u00a0Chem. Pharmaceut. Res."},{"key":"10.1016\/j.ejmech.2021.113222_bib36","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.arabjc.2014.10.053","article-title":"Synthesis of novel isoxazolines and isoxazoles of N-substituted pyrazolo[3,4-d]pyrimidin-4(5H)-one derivatives through [3+2] cycloaddition","volume":"12","author":"Rahmouni","year":"2019","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.ejmech.2021.113222_bib37","doi-asserted-by":"crossref","first-page":"1700311","DOI":"10.1002\/ardp.201700311","article-title":"Design, synthesis, and biological evaluation of novel 1,2-diaryl-4-substituted-benzylidene-5(4H)-imidazolone derivatives as cytotoxic agents and COX-2\/LOX inhibitors","volume":"351","author":"Lamie","year":"2018","journal-title":"Arch. Pharm. Chem. Life Sci."},{"key":"10.1016\/j.ejmech.2021.113222_bib38","doi-asserted-by":"crossref","first-page":"102978","DOI":"10.1016\/j.bioorg.2019.102978","article-title":"Design and synthesis of new benzoxazole\/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents","volume":"89","author":"Philoppes","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.113222_bib39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/157015906775203002","article-title":"Animal models for the development of new neuropharmacological therapeutics in the Status Epilepticus","volume":"4","author":"Mart\u00edn","year":"2006","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejmech.2021.113222_bib40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0920-1211(01)00272-8","article-title":"Repeated low dose treatment of rats with pilocarpine: low mortality but high proportion of rats developing epilepsy","volume":"46","author":"Glien","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejmech.2021.113222_bib41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0003-2697(79)90738-3","article-title":"Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction","volume":"95","author":"Ohkawa","year":"1979","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejmech.2021.113222_bib42","first-page":"882","article-title":"Improved method for the determination of glutathione","volume":"61","author":"Beutler","year":"1963","journal-title":"J.\u00a0Lab. Clin. Med."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421000714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421000714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:19:23Z","timestamp":1759328363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421000714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":42,"alternative-id":["S0223523421000714"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113222","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M\/HER2 inhibitors: Design, synthesis, structure\u2013activity relationship and biological activity as potential antitumor and anticonvulsant agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113222"}}